US 12,343,349 B2
Imipramine for use as an inhibitor of Fascin1 overexpression
Pablo Conesa Zamora, Murcia (ES); Horacio Perez Sanchez, Guadalupe (ES); Irene Luque Fernández, Granada (ES); Silvia Montoro García, Guadalupe (ES); Begoña Alburquerque Gonzalez, Guadalupe (ES); Priscila Campioni Rodrigues, Oulu (FI); José García Solano, Murcia (ES); Angel Bernabé García, Murcia (ES); Francisco José Nicolás Villaescusa, Murcia (ES); Manuel Bernabé García, Murcia (ES); Maria Luisa Cayuela Fuentes, Murcia (ES); Javier Ruiz Sanz, Granada (ES); Jose Cristobal Martínez Herrerías, Granada (ES); and Tuula Salo, Helsinki (FI)
Assigned to FUNDACION UNIVERSITARIA SAN ANTONIO, Granada (ES); FUNDACION PARA LA FORMACIÓN E INVESTIGACIÓN SANITARIAS, Murcia (ES); and UNIVERSIDAD DE GRANADA, Granada (ES)
Appl. No. 17/281,084
Filed by FUNDACION UNIVERSITARIA SAN ANTONIO, Guadalupe (ES); FUNDACION PARA LA FORMACIÓN E INVESTIGACIÓN SANITARIAS, Murcia (ES); and UNIVERSIDAD DE GRANADA, Granada (ES)
PCT Filed Sep. 22, 2019, PCT No. PCT/ES2019/070631
§ 371(c)(1), (2) Date Mar. 29, 2021,
PCT Pub. No. WO2020/065113, PCT Pub. Date Apr. 2, 2020.
Claims priority of application No. 18382696 (EP), filed on Sep. 28, 2018.
Prior Publication US 2023/0330096 A1, Oct. 19, 2023
Int. Cl. A61K 31/55 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/55 (2013.01) [A61P 35/00 (2018.01)] 6 Claims
 
1. A method for the treatment of cancer mediated by fascin1 comprising administering to a subject in need thereof an effective amount of imipramine.